JG
NRIX icon

Jain Global’s Nurix Therapeutics NRIX Stock Holding History

Jain Global’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
+64,661
New +$1.1M 0.01% 841
2025
Q4 		– Sell
-26,818
Closed -$248K – 1437
2025
Q3 		$248K Buy
+26,818
New +$278K ﹤0.01% 852

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jain Global's NRIX Position: Q2 2026 in Review

Jain Global opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 64,661 shares worth $1.57M. The stake represents 0.01% of the portfolio and ranks #841 among its holdings. This is a return to the name: Jain Global previously reported a position in NRIX as recently as Q3 2025.

Jain Global first reported a position in NRIX in Q3 2025 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Jain Global held 64,661 shares of Nurix Therapeutics worth $1.57M as of Q2 2026.
  • Nurix Therapeutics was a new Jain Global position in Q2 2026.
  • Nurix Therapeutics made up 0.01% of Jain Global's portfolio in Q2 2026, its #841 holding.
  • Jain Global first reported a position in Nurix Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.